How fast will the EU HTA child grow?

Estimation of the number of procedures of the first years of implementation

Authors: Buchholz ISL, Rehkopf J, Vinzens S, Hantke I, Schönermark MP

ISPOR Europe 2023 Posterpräsentation

Die Publikation ist ausschließlich auf Englisch verfügbar.


According to Regulation (EU) 2021/2282, the joint clinical assessment (JCA) will initially be implemented for oncology drugs and ATMPs applying for EMA marketing authorization from January 2025. Orphan drugs will subsequently follow in January 2028, and in January 2030, all centrally approved drugs will be subject to joint European clinical evaluation. Due to the staggered entry into the mandatory EU HTA process, the question arises as to how many procedures are completed within the first years. EU HTA is expected to be a learning system. But how many procedures will we be able to learn from?


The vast majority of EMA-approved medicines will eventually enter the German market and undergo the German benefit assessment "AMNOG". Thus, we extrapolated the procedural volume for JCAs per indication area in the first years of EU HTA implementation from the respective German HTA procedures. Various aspects of EU HTA obligation must be taken into account, such as the specific conditions for indication extension procedures.


For initially submitted oncology drugs and ATMPs, approximately 20 procedures per year are expected. From January 2028, orphan drugs will then increase the number of estimated JCA procedures by a dozen per year. Indication extensions were counted separately and represent only a few additional procedures.


There is a high degree of uncertainty in the EU HTA process as it is still taking shape. In the first years, there will be few orienting precedents that could be used as learning cases – for both the authorities and the manufacturers. In addition, in the gap years between late 2023 and early 2025, only 14 consultations are planned at the European level, which could not prepare numerically for the estimated EU HTA procedures. Capacity bottlenecks are to be expected and should be addressed proactively.

Kontaktieren Sie uns

Ihr Ansprechpartner Dr. rer. nat. Ingo Hantke
Dr. rer. nat. Ingo Hantke
M. Sc. Life Science
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 – 18


Hier stellen wir Ihnen unsere englisches Poster als kostenlosen Download zur Verfügung.

How fast will the EU HTA child grow? Estimation of the number of procedures in the first years of implementation

Market Access Strategie

Entwickeln Sie frühzeitig mit uns eine fundierte Market Access Strategie, welche Ihnen und allen Beteiligten eine wertvolle Orientierung während des gesamten Marktzugangs gibt.


Mit unseren agilen Value Dossiers erhalten Sie eine evidenzbasierte Nutzenargumentation, welche die Geschichte vom Mehrwert des Produktes (Value Story) strategisch und logisch in das Gesamtdokument einbindet.
nach oben